Locations:
Min Investment:
Max Investment:
Target Investment:
Executive Course on Venture Capital
(2016 - 2016)
(2001 - 2003)
2023
2017 - 2023
2019 - 2023
2017 - 2019
2021 - 2022
2021 - 2022
2017 - 2017
2017 - 2017
Proterris is a P2 clinical-stage firm that has pooled a dominant IP position in therapeutic uses of inhaled and small-molecule carbon monoxide.
2016 - 2017
2016 - 2017
Tonic App is a digital health company developing a tool for optimal communication between clinicians.
2015 - 2017
2015 - 2017
Lymphact is developing unique gamma-delta T-cell based therapeutics in the immuno-oncology field.
2015 - 2017
2015 - 2017
Immunethep developed a platform immunotherapy, based on robust and groundbreaking science, that dramatically reduces virulence across a wide range of bacterial strains responsible for serious and life-threatening infections.
2015 - 2017
2015 - 2017
Portugal Ventures is, currently, the largest Venture Capital operator in Portugal, focused on early stage (seed) investments. David's current focus is on: - Evaluating investment opportunities in the Portuguese Life Sciences and MedTech Space. - Accompanying invested companies through the investment cycle.
2012 - 2015
2012 - 2015
Triple Helix Technologies, Lda (THT), is a boutique consultancy catering to research institutions, offering services in grant sourcing and management, technology transfer and intellectual property protection. David Cristina, during his time at THT has been mostly responsible for the technology transfer and intellectual property areas, having worked on several engaging projects, namely: - Managed a significant IP portfolio (valued at over 1 M euros) - Oversaw patent protection for market-oriented clinical technology - Wrote several business plans, two of which went on to attract over 500.000 euros in seed financing - Designed and implemented the IP policy for two separate research institutions
2011 - 2015
2011 - 2015
Initially co-nominated between the Secretary of State for Entrepreneurship and Innovation, Dr. Carlos Oliveira and the Secretary of State for Science, Dra Leonor Parreira. David's main focus is on policies affecting the interface between research and innovation.